Modulation of the structural properties of mesoporous silica nanoparticles to enhance the T1-weighted MR imaging capability

A1 Journal article (refereed)

Internal Authors/Editors

Publication Details

List of Authors: Didem Şen Karaman, Diti Desai, Jixi Zhang, Sina Tadayon, Gözde Unal, Jarmo Teuho, Jawad Sarfraz, Jan-Henrik Smått, Hongchen Gu, Tuomas Näreoja, Jessica M. Rosenholm
Publisher: Royal Society of Chemistry
Publication year: 2016
Journal: Journal of Materials Chemistry. B
Volume number: 4
Issue number: 9
Start page: 1720
End page: 1732
eISSN: 2050-7518


In this study, we have investigated the contrast enhancement of Gd(III) incorporated nanoparticle-based contrast agents (CA) by the modulation of the synthesis and structural parameters of the mesoporous silica nanoparticle (MSN) matrix. In the optimisation process, the structure of the MSN matrix, post-synthesis treatment protocols, as well as the source and incorporation routes of paramagnetic gadolinium centers were considered, with the aim to shorten the T1 weighted relaxation time. After preliminary evaluation of the prepared MSNs as nanoparticulate T1/positive contrast agents based on relaxivity, the structure of the MSN matrix was affirmed as the most decisive property to enhance the r1 relaxivity value, alongside the incorporation route of paramagnetic Gd(III) centers. Based on these findings, the most promising Gd(III) incorporated MSN-based CA candidate was further evaluated for its cytocompatibility and intensity enhancement by in vitro phantom MR-imaging of labeled cells. Furthermore, pre-labeled tumors grown on a chick embryo chorioallantoic membrane (CAM) were imaged as an in vivo model on a 3T clinical MRI scanner. Our findings show that the optimized MSN-based CA design enables proper access of water to Gd-centers in the selected MSN matrices, and simultaneously decreases the required amount of Gd(III) content per mass when evaluated against the other MSNs. Consequently, the required Gd amount on a per-dose basis is significantly decreased with regard to clinically used Gd-based CAs for T1-weighted MR imaging.

Last updated on 2020-05-08 at 04:26